Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate September 30, 2025
Crystalys Therapeutics Launches with $205M Series A Financing to Transform the Treatment of Gout September 30, 2025
Avenzo collects another $60M for two small molecules and two ADCs licensed from China September 22, 2025
Evommune Presents Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria During Late-Breaker at EADV 2025 Congress September 19, 2025
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025 September 18, 2025
